A new data standard for multiple sclerosis has been released by the Clinical Data Interchange Standards Consortium.
A new data standard for multiple sclerosis (MS) has been released by the Clinical Data Interchange Standards Consortium (CDISC), the leading global standards organization for clinical research. When used together with the foundational CDISC clinical data standard, this therapeutic area standard allows clinical research data from multiple MS trials to be grouped for reporting, analysis, and regulatory submissions.
The standard is the result of work from organizations across the globe. Led by the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a Critical Path Institute (C-Path) consortium, the effort drew on the ‘common data elements’ developed for MS through the National Institute of Neurological Disorders and Stroke (NINDS). MSOAC members with clinical expertise in MS connected with CDISC teams in the standardization process designed by the Coalition for Accelerating Standards and Therapies (CFAST) initiative. In the CFAST standardization process, standards developers work closely with clinical experts on definitions and scoping from the beginning.
Like other open CDISC data standards, the new MS standard is freely available (http://www.cdisc.org/therapeutic#MS). “This new tool is more than another resource for the MS research community, ” indicated Dr. Timothy Coetzee, Chief Advocacy, Services and Research Officer at the National MS Society. “This new MS standard signals a commitment to ensure that data does not remain in silos. By standardizing data we expect that research will move us faster toward our goal of a world free of MS.”
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.